Current Evidence on the Lipid-Lowering Efficacy and Safety of Oral PCSK9 Inhibitors: A Systematic Review and Meta-analysis
Background: Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established therapeutic strategy for significantly reducing low-density lipoprotein cholesterol (LDL-C) levels. In recent years, new oral PCSK9 inhibitors have been developed, providing emerging evidence regarding their lipid-...